Does a high arachidonic acid-to-EPA ratio increase inflammatory potential?

The ratio of arachidonic acid (AA) to eicosapentaenoic acid (EPA) in tissue and membrane phospholipids serves as a critical biological rheostat for systemic inflammatory tone.

Biochemical mechanisms of substrate competition

• Enzymatic competition: AA and EPA compete directly as substrates for the active sites of cyclooxygenase (COX-1/COX-2) and lipoxygenase (primarily 5-LOX) enzymes.
• Eicosanoid flux: An elevated AA:EPA ratio shifts metabolic pathways to favor the synthesis of highly potent, AA-derived 2-series prostaglandins (PGE₂ and thromboxane A₂) and 4-series leukotrienes (LTB₄), which initiate and amplify vascular and cellular immune responses, pain, fever, and leukocyte recruitment.
• Loss of resolution: Conversely, a lower ratio promotes the generation of weaker 3-series prostaglandins (PGE₃), 5-series leukotrienes (LTB₅), and E-series resolvins (RvE1–RvE4), which function as specialized pro-resolving mediators (SPMs) that actively limit leukocyte infiltration and promote tissue homeostasis.

Systemic inflammatory potential

• Biomarker elevation: Shifting cellular lipid environments toward AA-derived eicosanoid signaling drives increased systemic inflammatory potential, correlating with elevated downstream circulating biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).
• Therapeutic modulation: Elevating cellular EPA concentrations successfully displaces AA from membrane phospholipids, mitigating pro-inflammatory cytokine cascades and lowering overall biological inflammatory tone.

Bottom line

• An elevated AA:EPA ratio biochemically drives systemic inflammatory potential by shifting enzymatic pathways to favor highly active, pro-inflammatory AA-derived eicosanoids over less potent, actively resolving EPA-derived mediators.